Evidence map›Paper›PMID 33163950›Full record

ReviewJHEP reports : innovation in hepatology2020

NAFLD and liver transplantation: Disease burden, current management and future challenges.

Patrizia Burra, Chiara Becchetti, Giacomo Germani

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in JHEP reports : innovation in hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 9 pooled it
16.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 9 syntheses or guidelines pooled it, 214 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Guideline
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Patrizia BurraMultivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital Padua, University of Padua, Padua, Italy.
Chiara BecchettiMultivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital Padua, University of Padua, Padua, Italy.
Giacomo GermaniMultivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, University Hospital Padua, University of Padua, Padua, Italy.
University of Padua · ITUniversity Hospital of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD), specifically its progressive form non-alcoholic steatohepatitis (NASH), represents the fastest growing indication for liver transplantation in Western countries. Diabetes mellitus, morbid obesity and cardiovascular disease are frequently present in patients with NAFLD who are candidates for liver transplantation. These factors require specific evaluation, including a detailed pre-surgical risk stratification, in order to improve outcomes after liver transplantation. Moreover, in the post-transplantation setting, the incidence of cardiovascular events and metabolic complications can be amplified by immunosuppressive therapy, which is a well-known driver of metabolic alterations. Indeed, patients with NASH are more prone to developing early post-transplant complications and, in the long-term,

Indexed as

CKD, chronic kidney diseaseCNI, calcineurin inhibitorsDM, diabetes mellitusDPP-4, dipeptidyl peptidase-4ELTR, European Liver Transplant RegistryESLD, end-stage liver diseaseGLP1 RAs, glucagon-like peptide-1 receptor agonistsGraft survivalHCC, hepatocellular carcinomaHR, hazard ratioHypertensionImmunosuppressantIRR, incidence rate ratioLT, liver transplantMAFLD, metabolic dysfunction-associated fatty liver diseaseMetabolic complicationmTORi, mammalian target of rapamycin inhibitorsNAFLD, non-alcoholic fatty liver diseaseNASH, non-alcoholic steatohepatitisNew-onset diabetes after transplantationNon-alcoholic fatty liver diseaseNon-alcoholic steatohepatitisObesityOR, odds ratioPatient survivalSGLT2, sodium-glucose co-transporter-2Solid organ transplantationUNOS, United Network for Organ Sharing

Identifiers

PMID33163950
PMCPMC7607500
OpenAlexW3092391366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.